Lack of retroperitoneal lymphadenopathy predicts survival of patients with metastatic renal cell carcinoma.

@article{Vasselli2001LackOR,
  title={Lack of retroperitoneal lymphadenopathy predicts survival of patients with metastatic renal cell carcinoma.},
  author={James R Vasselli and James C Yang and W. Marston Linehan and Donald E. White and Steven A Rosenberg and M. M. Walther},
  journal={The Journal of urology},
  year={2001},
  volume={166 1},
  pages={68-72}
}
PURPOSE Patients with metastatic renal cell carcinoma have a reported 5-year survival of 0% to 20%. The ability to predict which patients would benefit from nephrectomy and interleukin-2 (IL-2) therapy before any treatment is initiated would be useful for maximizing the advantage of therapy and improving the quality of life. MATERIALS AND METHODS A retrospective analysis of the x-rays and charts of patients treated at the National Institutes of Health Surgery Branch between 1985 and 1996, who… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 50 extracted citations

Patient outcome and prognostic factors of renal cell carcinoma in clinical stage T(1-3)N(1-2)M(0): a single-institution analysis.

Nan fang yi ke da xue xue bao = Journal of Southern Medical University • 2011
View 9 Excerpts
Highly Influenced

The role of lymph node dissection in renal cell carcinoma

International Journal of Clinical Oncology • 2011
View 5 Excerpts
Highly Influenced

Lymph Node Dissection for Small Renal Masses.

The Urologic clinics of North America • 2017
View 1 Excerpt

Similar Papers

Loading similar papers…